Optimal Outcomes in Young Class 3 Patients With Thalassemia Undergoing HLA-Identical Sibling Bone Marrow Transplantation
Authors:
- Antonella IsgròAIAntonella Isgrò
- Pietro SodaniPSPietro Sodani
- Marco MarzialiMMMarco Marziali
- Katia PaciaroniKPKatia Paciaroni
- Cristiano GallucciCGCristiano Gallucci
- Gioia De AngelisGAGioia De Angelis
- Marco AndreaniMAMarco Andreani
- Manuela TestiMTManuela Testi
- Cecilia AlfieriCACecilia Alfieri
- Michela RibersaniMRMichela Ribersani
- Tiziana GalluccioTGTiziana Galluccio
- 1 April 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (4) , 925-932
Abstract
Bone marrow transplantation (BMT) for class 3 patients with thalassemia is challenging due to high rates of graft rejection and transplant-related mortality. Since the first studies of BMT in the late 1980s, a number of conditioning regimens have been designed to improve outcomes, but with suboptimal results. Here we report the outcome of transplantation in class 3 patients using a modified protocol. Sixty-three patients between 5 and 16.7 years of age with class 3 thalassemia received HLA-matched sibling BMT following either the original protocol (26 patients) or the modified protocol (37 patients). Both regimens comprised preconditioning cytoreduction with hydroxyurea and azathioprine starting at -45 days pretransplant, and fludarabine from days -16 to -12. Conditioning was performed with busulfan and cyclophosphamide (original protocol) or with busulfan, thiotepa, and cyclophosphamide (modified protocol). The 2 groups showed similar patient demographics. At day 0, the degree of cytoreduction (lymphopenia, neuthropenia, and thrombocytopenia) achieved by the modified protocol was greater than the original protocol. The incidence of graft failure/rejection was significantly higher in the original group (15%; 95% confidence interval [95% CI], 5-32%) compared with the modified group (0%) (P = 0.014). The respective 5-year thalassemia-free survival rates were 73% (95% CI, 51-86%) and 92% (95% CI, 77-97%) (P = 0.047). Both groups showed similar incidences of grades II to IV acute graft-versus host disease. Modified protocol did not increase nonhematological toxicity or infectious complications. The modified treatment protocol effectively and safely prevented graft failure/rejection and significantly increased thalassemia-free survival of class 3 patients with thalassemia.Keywords
This publication has 39 references indexed in Scilit:
- Allogeneic Cellular Gene Therapy for HemoglobinopathiesHematology/Oncology Clinics of North America, 2010
- Advances in the allogeneic transplantation for thalassemiaBlood Reviews, 2008
- Long‐term results of survival in patients with thalassemia major treated with bone marrow transplantationAmerican Journal of Hematology, 2008
- New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 yearsBlood, 2004
- Complications of β-thalassemia major in North AmericaBlood, 2004
- The cure of thalassemia by bone marrow transplantationBlood Reviews, 2002
- Marrow transplantation for patients with thalassemia: results in class 3 patientsBlood, 1996
- Bone Marrow Transplantation in ThalassemiaHematology/Oncology Clinics of North America, 1991
- Bone Marrow Transplantation in Patients with ThalassemiaNew England Journal of Medicine, 1990
- MARROW TRANSPLANTATION FOR THALASSAEMIAThe Lancet, 1982